<DOC>
	<DOCNO>NCT00948506</DOCNO>
	<brief_summary>This two-arm , single center placebo-controlled double-blind proof concept study evaluate safety efficacy topical cidofovir ( 1 % 3 % ) compare placebo prevention hair growth .</brief_summary>
	<brief_title>Trial Topical Cidofovir Prevention Hair Growth</brief_title>
	<detailed_description>This phase II randomize , placebo control double blind , dose-ranging clinical trial topical cidofovir prevention hair growth . This proof concept study evaluate 1 % 3 % cidofovir petrolatum topically apply day target treatment area hair bear area face know beard area . This target area circular shape diameter three centimeter along jaw line one side face.The first 14 enrolled subject study randomize 1:1 fashion receive either 1 % topical cidofovir placebo 3 % topical cidofovir placebo . The last cohort subject enrol study achieve total 16 evaluable subject receive 3 % formulation placebo . Subjects also randomize side face ( left right ) receive active drug versus placebo . Subjects treat eight week . Any subject achieve 100 % alopecia ( correspond 0 PGA Hair Density ) treat area prior eight week classify responder discontinue active treatment begin four week observation period . From time discontinue treatment , subject follow four week time safety data collect .</detailed_description>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>1 . Subjects must able give informed consent . 2 . Subjects must male , age 18 year old . 3 . Score 4 5 Physician 's Global Assessment Hair Density baseline 4 . Subjects must shave least day avoid visible beard hair length skin line . 5 . Male subject sexually active female partner capable fertilization must ensure female partner either postmenopausal , surgically incapable childbearing , use medically acceptable method contraception throughout entire study period . Medically acceptable method contraception may use subject and/or partner include oral contraceptive patch , diaphragms spermicide , IUD , condom spermicide , progestin implant injection . Female partner take oral contraceptive must take consistently least two month prior subject receive study medication . 6 . Subjects must able limit use alcohol 2 few drink per day duration study period . One drink correspond 6 oz wine , 12 oz beer 1 oz hard liquor . 7 . Subjects must willing able avoid exposure study drug others 8 . Subjects must able understand comply drug storage application procedures 1 . Use investigational medication 180 day prior study enrollment ( day 0 ) . 2 . Use topical medication affect hair growth 8 week prior baseline visit ( e.g . minoxidil , eflornithine HCl ) . 3 . Use systemic medication affect hair growth 180 day prior baseline visit ( e.g . minoxidil , cyclosporine A , finasteride ) . 4 . Clinically significant abnormality liver function , renal function , chemistry panel CBC ( AST ALT ≥ 2 time laboratory 's upper limit normal , hemoglobin &lt; 10.0 g/dL , platelet count &lt; 125,000/cm3 , white blood count &lt; 3,500 cells/cm3 &gt; 15,000 cells/cm3 , serum creatinine ≥ 1.5 mg/dL ) within two week baseline visit . 5 . Proteinuria hematuria upon urine analysis within two week baseline visit . 6 . Active inflammatory skin disease treatment area ( e.g . acne , cyst ) neoplasms treatment area judgment investigator precludes enrollment . 7 . History skin cancer actinic keratoses treatment area . 8 . Concomitant use topical medication target area study . 9 . Previous history alopecia areata . 10 . Use nephrotoxic medication ( tobramycin , gentamycin , amikacin , amphotericin B , foscarnet , vancomycin , nonsteroidal antiinflammatory agent ) 7 day prior baseline visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>